In an independent experiment, encorafenib or binimetinib (MEK inhibitor) alone showed a rapid blockage of the MAPK pathway after 30 minutes in a preclinical model of melanoma, a tumor type with very good response to BRAF inhibitor single agent, as well as in BRAFV600E PMP cells (Supplementary Fig. S5B and S5C left). This evidence concerns the gene BRAF and neoplasm.